Daniel Gilbert

Washington, D.C., United States

Business of Medicine Reporter at The Washington Post

Writing about the business of medicine for @washingtonpost. Priors @seattletimes investigations, @wsj. Signal: 773-350-6933, email: [email protected]

Featured in: Favicon

washingtonpost.com Favicon

msn.com

wsj.com

yahoo.com (+9) Favicon

sfgate.com Favicon

entrepreneur.com Favicon

marketwatch.com Favicon

sagepub.com (+1) Favicon

stuff.co.nz Favicon

thestar.com + 95 more

Articles

Trump Pledges Tariffs On Pharmaceuticals, Setting Up Fight Over Who Pays

2 weeks ago | southfloridareporter.com | Daniel Gilbert

President Donald Trump is pledging to target the pharmaceutical industry with tariffs even while pausing many of his global levies for 90 days, threatening to disrupt international supply chains and raising the prospect of a clash between drugmakers and insurers that could determine whether patients are hit with higher costs.
Trump pledges tariffs on pharmaceuticals, setting up fight over who pays

2 weeks ago | washingtonpost.com | Daniel Gilbert

Trump pledges tariffs on pharmaceuticals, setting up fight over who pays (washingtonpost.com) Trump pledges tariffs on pharmaceuticals, setting up fight over who pays By Daniel Gilbert 2025041010004900 President Donald Trump is pledging to target the pharmaceutical industry with tariffs even while pausing many of his global levies for 90 days, threatening to disrupt international supply chains and raising the prospect of a clash between drugmakers and insurers that could determine whether...
Biotech start-ups struggle as Trump throttles NIH funding

2 weeks ago | washingtonpost.com | Daniel Gilbert

Biotech start-ups struggle as Trump throttles NIH funding (washingtonpost.com) Biotech start-ups struggle as Trump throttles NIH funding By Daniel Gilbert 2025040612002600 The Trump administration's deep rollbacks on medical research funding are eroding a key pillar of the American biotechnology industry, weakening a financial bridge that helps scientists translate laboratory discoveries into therapies that benefit patients.
Why 23andMe failed to innovate in drugs and health care despite a DNA trove

4 weeks ago | washingtonpost.com | Daniel Gilbert

23andMe burst onto the scene by collecting saliva samples from millions of customers and revealing their ancestries, but it aspired to do much more: developing new medicines and providing personalized health care, all powered by the engine of its unique trove of genetic data.
Companies warn investors that DOGE’s federal cuts might hurt business

1 month ago | seattletimes.com | Douglas MacMillan |Daniel Gilbert |Aaron Schaffer

Elon Musk’s sweeping makeover of the federal government in recent weeks is reverberating across the private sector, where companies have started expressing fear and uncertainty about disruptions these changes might inflict on their businesses.
Companies warn investors that DOGE’s federal cuts might hurt business

1 month ago | washingtonpost.com | Doug MacMillan |Aaron Schaffer |Daniel Gilbert

Elon Musk’s sweeping makeover of the federal government in recent weeks is reverberating across the private sector, where companies have started expressing fear and uncertainty about disruptions these changes might inflict on their businesses.
Novo Nordisk offering Wegovy for $499 a month for uninsured weight-loss patients

1 month ago | washingtonpost.com | Daniel Gilbert

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1,349 list price. The Danish drugmaker is launching a pharmacy operation that will provide the prescription medication at all doses directly to patients who lack insurance or whose health plan doesn’t cover obesity medications.
Eli Lilly says it will spend billions to move drug manufacturing to U.S. soil

1 month ago | washingtonpost.com | Daniel Gilbert

Eli Lilly said Wednesday it will build three manufacturing plants in the United States to make the keyraw ingredients in its medicines, a push to bring home a critical part of the pharmaceutical supply chain that largely comes from foreign sources.
FDA says shortage of Ozempic and Wegovy is over after more than two years

2 months ago | washingtonpost.com | Daniel Gilbert

The Food and Drug Administration said Friday the shortage of Ozempic and Wegovy is over, a step that could spell the end to a booming market of cheap, pharmacy-made weight-loss drugs that has attracted a huge patient following. The FDA said it will give compounding pharmacies until April or May, depending on their regulatory status, to stop making versions of semaglutide, the active ingredient in the brand-name drugs.
Black Hawk crew might not have heard crucial tower instruction, NTSB says

2 months ago | spokesman.com | Daniel Gilbert |Rachel Weiner

The crew of an Army Black Hawk helicopter might not have heard key instructions from air traffic control before a collision with a passenger jet over the Potomac River on Jan. 29, the National Transportation Safety Board said Friday in its most detailed account of the moments before the crash that killed 67 people.